LLY.DE

Eli Lilly and Company [LLY.DE] Stock Forecast

Q: What is Eli Lilly and Company stock symbol ?

Eli Lilly and Company is a US stock, located in Indianapolis of In and trading under the symbol LLY.DE

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

LLY.DE Stock Summary

Earnings are expected to rise 9.47% next year

LLY.DE's dividend payments are well covered by cash flows with cash payout ratio of 63.85%.

LLY.DE has less than 1 year of cash runway

Debt-to-Equity ratio of 1.7 is considered moderate, deeper research suggested.

Top 10 Correlated ETFs

LLY.DE

Top 10 Correlated Stocks

LLY.DE

In the News

LLY.DE Financial details

Company Rating

Strong Buy

Market Cap

494.11B

Income

6.5B

Revenue

29.52B

Book val./share

12.3

Cash/share

3.14

Dividend

4.37

Dividend %

0.79%

Employees

39K

Optionable

Shortable

Yes

Earnings

02 Nov 2023

P/E

76.23

Forward P/E

48.77

PEG

53.27

P/S

17.71

P/B

44.77

P/C

164.81

P/FCF

162.74

Quick Ratio

0.63

Current Ratio

1.13

Debt / Equity

1.7

LT Debt / Equity

1.64

EPS (TTM)

7.03

EPS next Y

10.61

EPS next Q

EPS this Y

12.68%

EPS next Y

50.93%

EPS next 5Y

50.93%

EPS last 5Y

17.15%

Revenue last 5Y

5.84%

Revenue Q/Q

19.43%

EPS Q/Q

38.03%

SMA20

2.95%

SMA50

30.02%

SMA100

34.36%

Inst Own

Inst Trans

ROA

12%

ROE

60%

ROC

0.21%

Gross Margin

78%

Oper. Margin

25%

Profit Margin

22%

Payout

59%

Shs Outstand

949.29M

Shs Float

897.49M

Target Price

52W Range

289.85-565.0

52W High

-8.41%

52W Low

+79.07%

RSI

Rel Volume

0.55

Avg Volume

1.96K

Volume

1.09K

Perf Week

-3.45%

Perf Month

3.19%

Perf Quarter

53.74%

Perf Half Y

66.43%

Beta

0.315006

Volatility

6.42%, 17.44%

Prev Close

-0.58%

Price

517.5

Change

-0.58%

LLY.DE Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	20.91	23.97	27.04	31.22	31.65
Net income per share	3.14	4.98	6.82	6.15	6.93
Operating cash flow per share	5.38	5.19	7.16	8.01	7.86
Free cash flow per share	2.44	3.74	4.93	5.94	5.1
Cash per share	7.21	2.62	4.06	4.31	2.45
Book value per share	9.56	2.8	6.22	9.9	11.81
Tangible book value per share	8.25	-8.16	-5.94	-2.68	-0.56
Share holders equity per share	9.56	2.8	6.22	9.9	11.81
Interest debt per share	10.29	17.4	18.68	18.99	18.38
Market cap	117.89B	122.01B	152.56B	251.44B	330.55B
Enterprise value	120.87B	135.48B	165.5B	264.51B	344.72B
P/E ratio	36.48	26.31	24.63	45.05	52.93
Price to sales ratio	5.48	5.47	6.22	8.88	11.58
POCF ratio	21.34	25.23	23.47	34.63	46.66
PFCF ratio	47.04	35.03	34.13	46.67	71.85
P/B Ratio	11.99	46.8	27.04	28	31.04
PTB ratio	11.99	46.8	27.04	28	31.04
EV to sales	5.62	6.07	6.74	9.34	12.08
Enterprise value over EBITDA	12.53	20.51	21.66	30.27	36.54
EV to operating cash flow	21.88	28.01	25.46	36.43	48.66
EV to free cash flow	48.22	38.9	37.02	49.1	74.93
Earnings yield	0.03	0.04	0.04	0.02	0.02
Free cash flow yield	0.02	0.03	0.03	0.02	0.01
Debt to equity	1.05	6.06	2.94	1.88	1.52
Debt to assets	0.23	0.4	0.36	0.35	0.33
Net debt to EBITDA	0.31	2.04	1.69	1.5	1.5
Current ratio	1.73	1.16	1.4	1.23	1.05
Interest coverage	22.74	12.42	16.85	18.71	21.49
Income quality	1.71	0.58	1.05	1.3	1.13
Dividend Yield	0.02	0.02	0.02	0.01	0.01
Payout ratio	0.72	0.52	0.43	0.55	0.57
Sales general and administrative to revenue	0.28	0.28	0.25	0.23	0.23
Research and developement to revenue	0.24	0.25	0.25	0.25	0.25
Intangibles to total assets	0.06	0.26	0.24	0.24	0.23
Capex to operating cash flow	-0.55	-0.28	-0.31	-0.26	-0.35
Capex to revenue	-0.14	-0.06	-0.08	-0.07	-0.09
Capex to depreciation	-1.88	-1.1	-1.53	-1.21	-1.63
Stock based compensation to revenue	0.01	0.01	0.01	0.01	0.01
Graham number	26.01	17.71	30.89	37.03	42.9
ROIC	0.26	0.23	0.23	0.22	0.24
Return on tangible assets	0.08	0.16	0.17	0.15	0.16
Graham Net	-19.18	-30.5	-32.99	-30.55	-30.97
Working capital	8.66B	1.93B	4.98B	3.4B	896.3M
Tangible asset value	8.47B	-7.6B	-5.39B	-2.43B	-504.2M
Net current asset value	-12.45B	-22.88B	-23.35B	-21.2B	-20.68B
Invested capital	1.05	6.06	2.94	1.88	1.52
Average receivables	5.52B	5.66B	6.24B	7.53B	8.34B
Average payables	1.31B	1.31B	1.51B	1.64B	1.8B
Average inventory	3.78B	3.14B	3.59B	3.93B	4.1B
Days sales outstanding	98.1	90.62	103.06	104.75	109.45
Days payables outstanding	94.11	108.64	106.95	83.38	106.29
Days of inventory on hand	241.54	246.68	264.95	193.96	237.27
Receivables turnover	3.72	4.03	3.54	3.48	3.33
Payables turnover	3.88	3.36	3.41	4.38	3.43
Inventory turnover	1.51	1.48	1.38	1.88	1.54
ROE	0.33	1.78	1.1	0.62	0.59
Capex per share	-2.94	-1.45	-2.24	-2.07	-2.75

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	7.21	7.71	7.68	7.33	9.24
Net income per share	1.06	1.61	2.04	1.42	1.96
Operating cash flow per share	0.91	2.43	1.66	1.82	0.7
Free cash flow per share	0.41	1.74	1.08	0.87	-0.23
Cash per share	3.04	3.04	2.33	3.87	3.14
Book value per share	9.49	11.18	11.21	11.79	12.3
Tangible book value per share	-3.03	-0.94	-0.53	0.14	0.19
Share holders equity per share	9.49	11.18	11.21	11.79	12.3
Interest debt per share	18.77	17.73	17.18	20	21.05
Market cap	289.14B	295.22B	348.31B	325.55B	420.9B
Enterprise value	303.33B	308.49B	362.48B	340.89B	437.03B
P/E ratio	75.89	50.84	44.94	60.52	59.68
Price to sales ratio	44.57	42.53	47.7	46.77	50.64
POCF ratio	352.31	135.12	220.49	188.12	666.09
PFCF ratio	782.09	188.69	340.12	393.61	-2.06K
P/B Ratio	33.84	29.32	32.71	29.09	38.04
PTB ratio	33.84	29.32	32.71	29.09	38.04
EV to sales	46.75	44.44	49.64	48.98	52.58
Enterprise value over EBITDA	145.81	128.43	151.49	200.05	188.38
EV to operating cash flow	369.6	141.2	229.46	196.98	691.61
EV to free cash flow	820.47	197.17	353.95	412.15	-2.14K
Earnings yield	0	0	0.01	0	0
Free cash flow yield	0	0.01	0	0	0
Debt to equity	1.97	1.58	1.52	1.69	1.7
Debt to assets	0.36	0.33	0.33	0.36	0.34
Net debt to EBITDA	6.82	5.52	5.92	9	6.95
Current ratio	1.1	1.13	1.05	1.3	1.13
Interest coverage	21.32	25.02	21.86	14.53	17.67
Income quality	0.86	1.5	0.82	1.29	0.36
Dividend Yield	0	0	0	0	0
Payout ratio	0.93	0.61	0.46	0.76	0.58
Sales general and administrative to revenue	0.24	0.22	0.23	0.25	0.23
Research and developement to revenue	0.27	0.26	0.27	0.29	0.28
Intangibles to total assets	0.24	0.23	0.23	0.21	0.2
Capex to operating cash flow	-0.55	-0.28	-0.35	-0.52	-1.32
Capex to revenue	-0.07	-0.09	-0.08	-0.13	-0.1
Capex to depreciation	-1.29	-1.71	-1.48	-2.49	-2.28
Stock based compensation to revenue	0.01	0.01	0.01	0.02	0.02
Graham number	15.03	20.14	22.68	19.39	23.29
ROIC	0.06	0.07	0.06	0.04	0.06
Return on tangible assets	0.03	0.04	0.05	0.03	0.04
Graham Net	-31.06	-29.3	-29.39	-30.72	-35.08
Working capital	1.49B	1.99B	896.3M	4.8B	2.42B
Tangible asset value	-2.73B	-849.8M	-504.2M	134.7M	166.9M
Net current asset value	-21.29B	-19.66B	-20.68B	-21.06B	-22.33B
Invested capital	1.97	1.58	1.52	1.69	1.7
Average receivables	7.74B	8B	8.44B	8.79B	9.1B
Average payables	1.55B	1.67B	1.81B	1.97B	2.25B
Average inventory	3.9B	3.87B	4.07B	4.43B	4.67B
Days sales outstanding	106.43	107.93	105.49	116.67	99.3
Days payables outstanding	104.39	95.93	112.24	111.53	123.2
Days of inventory on hand	245.33	218.35	250.55	251.45	238.95
Receivables turnover	0.85	0.83	0.85	0.77	0.91
Payables turnover	0.86	0.94	0.8	0.81	0.73
Inventory turnover	0.37	0.41	0.36	0.36	0.38
ROE	0.11	0.14	0.18	0.12	0.16
Capex per share	-0.5	-0.69	-0.58	-0.95	-0.93

LLY.DE Dividend History

LLY.DE Frequently Asked Questions

What is Eli Lilly and Company stock symbol ?

Eli Lilly and Company is a US stock , located in Indianapolis of In and trading under the symbol LLY.DE

What is Eli Lilly and Company stock quote today ?

Eli Lilly and Company stock price is $517.5 today.

Is Eli Lilly and Company stock public?

Yes, Eli Lilly and Company is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.96K
Market Capitalization 494.11B
Employee 39K
CEO Mr. David A. Ricks
Headquarters Indianapolis,IN,US
IPO Date 2007-12-27
Website https://www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.